Biolab signs agreement with Amgen and expands access for doctors and patients to treatment that reduces high cholesterol.
The Brazilian pharmaceutical company Biolab has signed an exclusive partnership with the American company Amgen for the commercialization of evolocumab. The monoclonal antibody is indicated for the treatment of mixed dyslipidemia and established atherosclerotic cardiovascular disease in adults, heterozygous and homozygous familial hypercholesterolemia in adult and pediatric patients aged ten and over. The companies' expectation is to enhance the therapeutic options for cardiologists and endocrinologists, providing greater access and quality of life for patients.
In force since August 2022, the agreement also reinforces Biolab's intense presence in the cardiovascular area and its constant quest to develop, produce and market innovative products. The partnership boosts the use of evolocumab, an effective treatment to combat heart disease, which affects around 14 million Brazilians and causes approximately 400,000 deaths a year, corresponding to 30% of all deaths in the country².
"We are excited about the partnership with Amgen, as patients and doctors now have more visibility of another treatment option to reduce LDL cholesterol. It is the first high-tech biological drug (monoclonal antibody) in Brazil in cardiology, used to treat dyslipidemia. The product has a lot of synergy with Biolab's cardiology portfolio, as we have an extensive line of drugs for the treatment of cardiovascular diseases. We now have a complete portfolio for all needs in the dyslipidemia segment," explains Dr. José Roberto da Costa Pereira, Biolab's Innovation and New Business Director.
"The decision to enter into a commercial agreement aims to join forces locally with Biolab, a partner that has been demonstrating common objectives in order to further expand knowledge of the impact of cardiovascular diseases and the need to increasingly establish what is recommended in the guidelines of the main cardiology societies in Brazil and worldwide," explains Alejandro Arancibia, Amgen's medical director.
"Biolab visits around 20,000 cardiologists and endocrinologists every month. With the agreement, we will be responsible for all medical promotion, distribution and patient support. By intensifying our work to disseminate information about the product, alert patients to the risk of dyslipidemia and offer an effective treatment option, we are taking another step towards reversing the endemic scenario of cardiovascular diseases in the country, as well as providing people with a better quality of life," said Cleiton de Castro Marques, Biolab's CEO.
About Biolab
Biolab Farmacêutica is a Brazilian company with an international presence that has innovation in its DNA. Founded in 1997, it was born with a focus on promoting health and science. It ranks among the most prescribed laboratories and has around 3,800 employees and one of the largest sales forces in the country. With a solid track record and more than 170 products in its portfolio, it is a leader in diversified markets, such as anti-hypertensive drugs in Cardiology, scar treatment and hair health in Dermatology, among others. It also stands out in Gynecology, Gastroenterology, Internal Medicine and Central Nervous System. The Generics division, founded in 2018, is one of the fastest-growing companies in the segment. Biolab has modern Research, Development and Innovation Centers in Brazil and Canada, and is responsible for the first national radical innovation and 400 patents filed. Find out more at www.biolabfarma.com.br.
About Amgen
Amgen is committed to using the full potential of biotechnology for patients suffering from serious diseases by discovering, developing and producing innovative medicines. This approach begins by using tools such as advanced genetics to unravel the biological basis of disease and thus, after broad understanding, develop molecules with well-defined targets and objectives. Amgen focuses on areas of unmet medical need, using all its experience in manufacturing products to find solutions that improve people's health and lives. Founded in the United States in 1980, Amgen has become the largest independent biotechnology company in the world, with millions of patients served and a pipeline of drugs with revolutionary potential in development. The company is constantly expanding, offering a robust portfolio in the areas of bone and cardiovascular diseases, hematology, inflammation, nephrology and oncology.
SC-BRA-AMG145-00471| Approved in August 2022 | Informative and institutional material about Amgen Brasil for the lay public.